ABTI

Alterola Biotech Inc

ABTI, USA

Alterola Biotech, Inc., a pharmaceutical company, engages in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products; production of active pharmaceutical ingredients and food-grade ingredients; and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech, Inc. is based in Birkenhead, the United Kingdom.

https://alterola-abti.com/

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ABTI
stock
ABTI

Kymera Therapeutics Stock Heads for Record. Why Investors Are Excited About Its Anti-Inflammatory Drug. Barron's

Read more →
ABTI
stock
ABTI

WATCH: Trump ‘wants to get' stock-trading ban done, Hawley insists after president's brutal attack on bill Fox News

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2024-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-3.64

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

33.67 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-50.72 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 0.00% of the total shares of Alterola Biotech Inc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-09-30

EPS Actual

-0.0005

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2024-09-30)

Deep Value
Weak Deep Value(1)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(3)
Value
Overpriced(3)

Income Statement

(Last Updated 2024-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.